Should all XXXX @entity1 be treated? Yes.

@entity1 @entity101 @entity25 @entity27 @entity751 @entity65
@entity27 ( @entity27 ) is a common condition. Whether an apnoeic @entity1 should be considered for treatment depends on the @entity751 , the rating of the severity and the potential morbidity associated with this condition. We have reviewed several types of evidence that early treatments of @entity27 deserved. There is a natural evolution of @entity27 leading to spontaneous aggravation and an increased @entity65 in untreated @entity1 in clinical populations. @entity25 ( @entity25 ), the key symptom of the disease, can be found with very low apnoea hypopnoea index (AHI) and eliminated by adequate treatment. @entity65 are present with very low AHI and there is a high relative risk of developing @entity101 in the future when @entity1 present with mild @entity27 at baseline. The effect of treatment is significant when compared with placebo in the mildest forms of the disease. The clinical benefit, however, is mainly expected in terms of consequences for behavioural morbidity (i.e. reversibility of @entity25 and its related consequences) as the impact on @entity65 is more doubtful and may anyway not be observed on a short-term follow-up. Overall, any @entity27 that is clearly responsible for @entity25 should be considered for treatment. Moreover, there is increasing evidence that the cardiovascular risk has to be taken into account when deciding on treatment, even in asymptomatic @entity1 . All this evidence put together suggests early treatment in @entity27 .
